Abstract:

Coronavirus disease caused by SARS-CoV-2 faces an unparalleled challenge in the pursuit of suitable drugs for prevention and treatment. Given the rapid speed of scientific study and clinical evidence provided by the vast number of people readily infected with SARS-CoV-2, clinicians need evidence of effective medical care for this infection. Although some recent COVID-19 trials have shown clinical progress, several of these trials are ongoing, including pharmacokinetics, the optimum dosage regimen and the therapeutic and treatment period, and even considering randomised controlled experiments. Antimalarial, anti-inflammatory and antibiotics are present clinical proof of their success in treating COVID-19 patients. Vaccination is one of the safest strategies for managing infection. Effective vaccines therefore need to be developed. Recent progress in the manufacture of coronaviras vaccines is outlined and current vaccine adjuvants for efficacy improvements are highlighted.

Keywords: COVID-19, SARS-CoV-2, Antimalarial, Antiviral, Immunomodulatory, Anti-inflammatory Drugs, Viral-vector Vaccines.